Key result
Cystatin C emerges as one of the most practically important novel biomarkers for determining prognosis in patients with chronic heart failure and preserved ejection fraction.
Why the study?
What is the prognostic value of biomarkers, including cystatin C, in patients with chronic heart failure and preserved ejection fraction?
What is the prognostic value of biomarkers, including cystatin C, in patients with chronic heart failure and preserved ejection fraction?
Answers are grounded in this paper and cite their sources.
This review highlights the prognostic utility of biomarkers, particularly cystatin C, in patients with chronic heart failure with preserved ejection fraction.
The paper reviews major biomarkers for determining the prognosis in patients with chronic heart failure and preserved ejection fraction. It also considers cystatin C, one of the novel and probably the most practically important biomarkers.
No takes yet. Share an insight, caveat, or question.
Nikiforova et al. (2016) studied this question. Cystatin C emerges as one of the most practically important novel biomarkers for determining prognosis in patients with chronic heart failure and preserved ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: